As on Tuesday, India saw a single-day rise of 4,417 Covid-19 cases, the lowest in three months, as per the government data.
New Delhi: The Drugs Controller General of India approved a nasal vaccine against Covid-19 developed by Bharat Biotech for “restricted use” among adults “in emergency situation”, said Union Health Minister Dr Mansukh Mandaviya in a tweet on Tuesday.
“Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Mandaviya said.
He added, “This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji’s leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19.”
The new vaccination is India’s first nasal vaccine against Covid-19. The firm completed the clinical trials of the nasal vaccine with about 4,000 volunteers and there are no side effects or adverse reactions reported so far, sources in the company told the media.
As on Tuesday, India saw a single-day rise of 4,417 Covid-19 cases, the lowest in three months, as per the government data. The number of active Covid cases has declined to 52,336, while there were 23 fatalities reported in the same period. According to the Union Health Ministry, the active cases now comprise 0.12% while the recovery rate has now increased to 98.69%, the Union Health Ministry said.
Development of vaccines is seeing a boost across the world. The British health authorities on Saturday approved a second “bivalent” vaccine to be used as a booster to target all strains of the Covid-19 virus.
